118 0

Full metadata record

DC FieldValueLanguage
dc.contributor.author최한곤-
dc.date.accessioned2018-06-11T05:26:45Z-
dc.date.available2018-06-11T05:26:45Z-
dc.date.issued2017-04-
dc.identifier.citationCOLLOIDS AND SURFACES B-BIOINTERFACES, v. 155, Page. 83-92en_US
dc.identifier.issn0927-7765-
dc.identifier.issn1873-4367-
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S0927776517301960-
dc.identifier.urihttps://repository.hanyang.ac.kr/handle/20.500.11754/71968-
dc.description.abstractWhen exposed to cancer cells, cytotoxic drugs such as doxorubicin (DOX) can lead to the induction of heat shock protein 90 (Hsp90), a molecular chaperone associated with a number of cancer-related client proteins, and result in cell survival. Co-administration of DOX with tanespimycin (TNP), an Hsp90 inhibitor, can sensitize the cancer cells to the cytotoxic effects of DOX. The effect of such a combination has been found to depend on the schedule of administration. Sequential administration of DOX and TNP has been linked to highly synergistic combination effects. Therefore, we aimed to develop folate-receptor targeted hybrid lipid-core nanocapsules comprising a hybrid lipid core lodging TNP and a polymeric corona lodging DOX (F-DTN). These nanocarriers were capable of delivering DOX and TNP sequentially, which was well demonstrated by an in vitro release study. The in vitro release profiles displayed pH-dependent and sustained release features. F-DTN exhibited excellent morphological characteristics with highly monodispersed particles. In vitro tests with F-DTN in MCF-7 cell line demonstrated exceptional cytotoxicity, with high cellular uptake and apoptosis. These findings were appreciably more assertive than tests with free individual drugs (DOX, TNP), free drug combination (DOX/TNP), or non-folate receptor-targeted hybrid lipid-core nanocapsules (DTN). In vivo pharmacokinetic study revealed noticeable enhancement of bioavailability and plasma circulation time of the drugs when encapsulated in the carrier system. Therefore, hybrid lipid-core nanocapsules have the potential to be utilized for application in folate receptor-targeted combination chemotherapy. (C) 2017 Elsevier B.V. All rights reserved.en_US
dc.description.sponsorshipThis research was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIP) (No. 2015R1A2A2A01004118, 2015R1A2A2A04004806).en_US
dc.language.isoen_USen_US
dc.publisherELSEVIER SCIENCE BVen_US
dc.subjectNanocapsules;en_US
dc.subjectSequential delivery;en_US
dc.subjectFolate receptor;en_US
dc.subjectDoxorubicin;en_US
dc.subjectTanespimycinen_US
dc.subjectMETASTATIC BREAST-CANCERen_US
dc.subjectDRUG-DELIVERYen_US
dc.subjectNANOPARTICLESen_US
dc.subjectTHERAPYen_US
dc.subjectCOMBINATIONen_US
dc.subjectCHEMOTHERAPYen_US
dc.subjectSYSTEMSen_US
dc.subjectENDOCYTOSISen_US
dc.subjectINHIBITIONen_US
dc.subjectCELLSen_US
dc.titleFolate receptor-targeted hybrid lipid-core nanocapsules for sequential delivery of doxorubicin and tanespimycinen_US
dc.typeArticleen_US
dc.relation.volume155-
dc.identifier.doi10.1016/j.colsurfb.2017.04.010-
dc.relation.page83-92-
dc.relation.journalCOLLOIDS AND SURFACES B-BIOINTERFACES-
dc.contributor.googleauthorGupta, Biki-
dc.contributor.googleauthorPathak, Shiva-
dc.contributor.googleauthorPoudel, Bijay Kumar-
dc.contributor.googleauthorRegmi, Shobha-
dc.contributor.googleauthorRuttala, Hima Bindu-
dc.contributor.googleauthorGautam, Milan-
dc.contributor.googleauthorLee, Jong Seong-
dc.contributor.googleauthorJeong, Jee-Heon-
dc.contributor.googleauthorChoi, Han-Gon-
dc.contributor.googleauthorYong, Chul Soon-
dc.contributor.googleauthorKim, Jong Oh-
dc.relation.code2017001472-
dc.sector.campusE-
dc.sector.daehakCOLLEGE OF PHARMACY[E]-
dc.sector.departmentDEPARTMENT OF PHARMACY-
dc.identifier.pidhangon-
Appears in Collections:
COLLEGE OF PHARMACY[E](약학대학) > PHARMACY(약학과) > Articles
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE